Alaa Alshehri

Alaa Alshehri

Auto-generated profile, based on publicly available information

Alaa Alshehri

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2024 in Primary Care Diabetes
Verified
Journal Article
Closed access
AAAlaa Alshehri
Alaa Alshehri
DGDawei Guan
Dawei Guan
PLPiaopiao Li
Piaopiao Li
YZYichen Zhang
Yichen Zhang
HGHans K. Ghayee
Hans K. Ghayee
HSHui Shao
Hui Shao

13 March 2025 in Health Affairs Scholar
Verified
Journal Article
Open access
SASumaya Abuloha
Sumaya Abuloha
BHBenjamin P Harvey
Benjamin P Harvey
SNShu Niu
Shu Niu
AAAlaa Alshehri
Alaa Alshehri
MMMelissa Miri
Melissa Miri
MSMikael Svensson
Mikael Svensson
Over the last 15 years, cancer drug prices have increased substantially in the United States (US), with question marks on whether this can be justified based on improved patient outcomes. This study aimed to analyze the relationship between US cancer drug net launch prices and clinical efficacy and certainty of evidence. FDA-approved cancer drug indications from 2008 to 2022 were extracted and matched with net launch price data, 5 distinct measures of clinical efficacy, and measures on the certainty of evidence around the clinical efficacy. Descriptive statistics and linear regression models were used to assess if higher net launch prices were associated with better patient outcomes. Cancer drug launch prices (net per 1 year/course of treatment) have increased from around $100 000 in 2008 to $200 000 in 2022. The results did not support the idea that drugs with higher net launch prices had more impressive clinical efficacy or more robust evidence around the clinical efficacy. US cancer launch prices do not seem to be value-based, which may imply distorted incentives for the allocation of research and development investments.